I trained as a nurse before I ever treated a patient with acne in aesthetic practice. The textbooks framed it simply: excess sebum, follicular plugging, Propionibacterium acnes, inflammation. Treat accordingly.
That model is incomplete. What we now understand about the skin microbiome has shifted the clinical picture, and practitioners who are not across this evidence are missing important consultation data.
Cutibacterium acnes is not the enemy
In 2016, the taxonomy changed. Propionibacterium acnes was reclassified as Cutibacterium acnes. The name shift reflects more than administrative housekeeping. It marks a broader recognition that this organism is a commensal, a normal resident of the sebaceous follicle, present in healthy skin and acne-affected skin alike.
The clinical question is not whether C. acnes is present. It almost always is. The question is which strain population is dominant, and what conditions allow pathogenic phylotypes to proliferate.
Research using 16S rRNA gene sequencing has shown that acne-affected skin carries a different distribution of C. acnes phylotypes compared with healthy skin. Phylotype IA, in particular, appears with higher frequency in inflammatory lesions. These distinctions matter because they begin to explain why two patients with similar sebaceous activity can have very different inflammatory outcomes.
What disrupts the microbiome in aesthetic patients
Aesthetic patients are not a general dermatology population. Many are adults. Many are managing acne alongside active skincare routines, professional-grade chemical exfoliants, and regular clinic treatments. Each of these can alter the microbial balance on the skin surface.
Frequent exfoliation shifts the surface pH. The commensal microbiome, including Staphylococcus epidermidis, which produces short-chain fatty acids that suppress pathogenic C. acnes strains, does not remain stable in a consistently disrupted barrier environment.
Strong surfactants reduce microbial diversity. Low-pH acids used repeatedly without recovery time suppress beneficial organisms as readily as problematic ones. Broad-spectrum topical antibiotics, particularly clindamycin and erythromycin used long-term, select for resistant strains and reduce the diversity of the entire skin microbiome.
NICE NG198 advises against antibiotic monotherapy for acne and recommends combining topical antibiotics with benzoyl peroxide to reduce resistance risk. What the guideline does not address, because it is a primary care document, is how repeated professional aesthetic treatments interact with those antibiotic courses. That is a clinical gap practitioners need to fill themselves.
The practical consultation implication
When I see a patient presenting with adult-onset or adult-persistent acne, the microbiome question sits behind several of my assessment points. What is their current home skincare protocol, and how often are they exfoliating? Do they have a history of prolonged antibiotic courses? Have they had repeated professional peels or microneedling sessions with no clear recovery phase between treatments? Are there any gut health issues that might be relevant?
None of those questions appear on a standard acne consultation form. Several should.
If a patient has completed three courses of topical clindamycin over two years and their acne has not resolved, antibiotic resistance is the most likely explanation. The microbial population has shifted. Repeating the same antibiotic is not the right clinical move. It is worth considering whether the barrier environment has been sufficiently repaired and whether benzoyl peroxide has been part of the treatment plan throughout.
Treatment planning with the microbiome in mind
A microbiome-aware treatment plan starts with the barrier. If the skin's acid mantle has been disrupted by aggressive home skincare, the first clinical conversation is about simplification, not addition. Many patients presenting to aesthetic practice are over-treating at home.
Benzoyl peroxide remains the most reliable topical option for managing C. acnes populations without promoting antibiotic resistance. No clinical resistance to benzoyl peroxide has been documented after decades of use. Combined with a retinoid, it addresses both microbial load and the comedone formation that provides the anaerobic environment C. acnes requires.
For patients with a history of repeated antibiotic use and treatment-resistant acne, the aesthetic practitioner's role is clear. Barrier restoration, microbiome support through product simplification, and maintenance once clearance is achieved. Acute systemic clearance belongs in a GP or dermatology referral pathway.
The microbiome is not a specialist topic that sits outside aesthetic practice. It is part of the clinical picture for every acne patient who walks through the door.
If you want a structured clinical framework for acne assessment and treatment planning that reflects current microbiome evidence, Acne Decoded covers the full consultation model, treatment selection, and prescribing considerations for UK practitioners. The course is £150 and available now.